| Ulcerative Colitis

Inflectra vs Xeljanz

Side-by-side clinical, coverage, and cost comparison for ulcerative colitis.

Deep comparison between: Inflectra vs Xeljanz with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsXeljanz has a higher rate of injection site reactions vs Inflectra based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Xeljanz but not Inflectra, including UnitedHealthcare

Category

Inflectra

Xeljanz

At A Glance

RouteIV infusion

FrequencyEvery 6-8 weeks

ClassTNF-alpha antagonist

RouteOral

FrequencyTwice daily

ClassJAK inhibitor

Indications

Ulcerative Colitis
Rheumatoid Arthritis
Ankylosing spondylitis
Arthritis, Psoriatic
Psoriasis vulgaris

Rheumatoid Arthritis
Arthritis, Psoriatic
Ankylosing spondylitis
Ulcerative Colitis
Juvenile polyarthritis

Dosing

Crohn's Disease, Ulcerative Colitis 5 mg/kg IV at 0, 2, and 6 weeks, then every 8 weeks; regimen applies to adult and pediatric patients >= 6 years.

Rheumatoid Arthritis 3 mg/kg IV at 0, 2, and 6 weeks, then every 8 weeks in combination with methotrexate; may increase up to 10 mg/kg every 8 weeks or as often as every 4 weeks for incomplete response.

Ankylosing spondylitis 5 mg/kg IV at 0, 2, and 6 weeks, then every 6 weeks.

Arthritis, Psoriatic, Psoriasis vulgaris 5 mg/kg IV at 0, 2, and 6 weeks, then every 8 weeks.

Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis Adults: 5 mg twice daily (XELJANZ) or 11 mg once daily (XELJANZ XR).

Ulcerative Colitis Induction: 10 mg twice daily or 22 mg once daily for at least 8 weeks (up to 16 weeks); maintenance: 5 mg twice daily or 11 mg once daily.

Juvenile polyarthritis Weight-based dosing in pediatric patients >=2 years weighing >=10 kg; patients >=40 kg: 5 mg twice daily.

Contraindications

Doses >5 mg/kg in patients with moderate or severe heart failure
Previous severe hypersensitivity reaction to infliximab products, inactive ingredients of INFLECTRA, or any murine proteins (including anaphylaxis, hypotension, and serum sickness)

—

Drug Interactions

1225View drug interactions

1069View drug interactions

Adverse Reactions

Most common (>10%) Infections (upper respiratory tract infection, sinusitis, pharyngitis), infusion-related reactions, headache, abdominal pain

Serious Serious infections (pneumonia, cellulitis, abscess, sepsis, tuberculosis, opportunistic infections), malignancies, lymphoma, hepatotoxicity (acute liver failure, autoimmune hepatitis), severe infusion reactions, lupus-like syndrome

Postmarketing Agranulocytosis, neutropenia, interstitial lung disease, Stevens-Johnson Syndrome, toxic epidermal necrolysis, peripheral demyelinating disorders (Guillain-Barre syndrome), acute liver failure, anaphylactic shock, cerebrovascular accidents, leukemia, melanoma, Merkel cell carcinoma

Most common (>=2%) Upper respiratory tract infection, nasopharyngitis, diarrhea, headache, hypertension.

Serious Serious infections (pneumonia, cellulitis, herpes zoster, urinary tract infection), malignancy, thrombosis, major adverse cardiovascular events, gastrointestinal perforations.

Postmarketing Drug hypersensitivity (angioedema, urticaria), acne.

Pharmacology

Infliximab-dyyb is a chimeric IgG1kappa monoclonal antibody TNF-alpha antagonist that neutralizes the biological activity of TNFalpha by binding with high affinity to soluble and transmembrane forms of TNFalpha, inhibiting receptor binding and downstream proinflammatory cytokine activity in RA, CD, UC, AS, PsA, and Ps.

Tofacitinib is a JAK inhibitor that blocks JAK1/JAK2, JAK1/JAK3, and JAK2/JAK2 signaling, preventing phosphorylation and activation of STATs to modulate immune cell function and hematopoiesis.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Inflectra